| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 07/20/2000 | CA2724287A1 Bifidobacterium in the treatment of inflammatory disease |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2360584A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | CA2360464A1 Human peptidases |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360358A1 Compositions having improved stability |
| 07/20/2000 | CA2360356A1 .beta.-phenylalanine derivatives as integrin antagonists |
| 07/20/2000 | CA2360243A1 Use of lactobacillus salivarius |
| 07/20/2000 | CA2360227A1 Pharmaceutical mixture comprising a combination of a profen and other active compounds |
| 07/20/2000 | CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359479A1 Novel complex-forming proteins |
| 07/20/2000 | CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2359392A1 Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
| 07/20/2000 | CA2358684A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 07/20/2000 | CA2356939A1 Modulation of systemic memory t cell trafficking |
| 07/20/2000 | CA2356776A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | CA2356611A1 New use of melagatran |
| 07/20/2000 | CA2355374A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/19/2000 | EP1020461A2 Use of alkaline salts of the (-)-enantiomer of omeprazole |
| 07/19/2000 | EP1020460A2 The sodium salt of the (-)-enantiomer of omeprazole |
| 07/19/2000 | EP1020179A2 Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition |
| 07/19/2000 | EP1019802A2 Method and system for pain management |
| 07/19/2000 | EP1019442A1 Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics |
| 07/19/2000 | EP1019434A2 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 07/19/2000 | EP1019431A1 Novel rnase p |
| 07/19/2000 | EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 07/19/2000 | EP1019410A1 Spiro-piperidine derivatives and their use as tachykinin antagonists |
| 07/19/2000 | EP1019406A1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019394A1 PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| 07/19/2000 | EP1019387A1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 07/19/2000 | EP1019386A1 Reverse hydroxamate derivatives as metalloprotease inhibitors |
| 07/19/2000 | EP1019382A1 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| 07/19/2000 | EP1019091A1 50 human secreted proteins |
| 07/19/2000 | EP1019089A2 Long-acting drugs and pharmaceutical compositions comprising them |
| 07/19/2000 | EP1019080A2 Modulation of lerk-2-mediated cell adhesion |
| 07/19/2000 | EP1019078A1 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| 07/19/2000 | EP1019063A1 Modulation of immune responses |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP0821551A4 Screening assay for the identification of inhibitors of macrophage migration inhibitory factor |
| 07/19/2000 | CN1260795A Quaternary ammonium compounds as tachykinin antagenists |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260782A Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
| 07/19/2000 | CN1260725A Conjugate composing folic acid antagonist and carrier |
| 07/19/2000 | CN1260721A Use of cartilage oligeomeric matrix protein for treatment of rheumatoid |
| 07/19/2000 | CN1260199A Multifunction quick-effect health medicinal plaster |
| 07/19/2000 | CN1260189A Application of radix scutellariae stem and leaf to pharmaceutical industry |
| 07/19/2000 | CN1054603C Tri-substituted phenyl derivatives and medicinal composition containing same |
| 07/19/2000 | CN1054599C Hydroxamic acid derivatives and preparation method and use |
| 07/19/2000 | CN1054533C Anti-inflammatory and pain-relieving capsule |
| 07/19/2000 | CN1054522C Sichuan aconite root analgesic soft extract |
| 07/19/2000 | CN1054509C Synergistic interplay of lymphokines and dsRNAs |
| 07/19/2000 | CN1054507C Preparation method for medicinal composition for treatment of vaginal infections |
| 07/18/2000 | US6090944 Alkanoic acid derivatives as αv integrin receptor antagonists |
| 07/18/2000 | US6090918 Polypeptide associated with the inhibition of prostaglandin biosynthesis and treating inflammation |
| 07/18/2000 | US6090914 CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| 07/18/2000 | US6090852 Matrix metalloprotease inhibitor |
| 07/18/2000 | US6090840 Peptidyl compounds having MMP and TNF inhibitory activity |
| 07/18/2000 | US6090826 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| 07/18/2000 | US6090817 Respiratory system disorders; phosphodiesterse inhibitor |
| 07/18/2000 | US6090816 Antiasthma agents |
| 07/18/2000 | US6090811 Analgesic |
| 07/18/2000 | US6090777 Administering exogenous c1-esterase inhibitor, alone or with other drugs to a patient with acute myocardial infarction or at risk for acute myocardial infarction |
| 07/18/2000 | US6090583 Expression system in compatible host cell of a polynucleotide which produces a metalloprotease; diagnosis and treatment of asthma, disorders of leukotriene metabolism; anticarcinogenic agents; antiinflammatory/antidiabetic/antiarthritic agents |
| 07/18/2000 | US6090579 Human SDR2 cDNA clone |
| 07/18/2000 | US6090544 Screening for compounds capable of activating osteogenic protein-1-responsive transcription activating element by transforming cell with dna of element linked to reporter gene, exposing cell to compound, determining gene expression |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | CA2017376C Diarylstyrylquinoline diacids |
| 07/18/2000 | CA2017315C Interleukin i inhibitor |
| 07/18/2000 | CA2008616C Aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
| 07/18/2000 | CA2004332C Inhibition of cell adhesion |
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040600A1 Selective inhibitors of mmp-12 |
| 07/13/2000 | WO2000040597A1 Method and composition for angiogenesis inhibition |
| 07/13/2000 | WO2000040592A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | WO2000040583A2 Imidazo[4,5-c]-pyridine-4-on-derivatives |
| 07/13/2000 | WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040576A2 Thiopyran compounds as inhibitors of mmp |
| 07/13/2000 | WO2000040562A1 2-oxoquinoline compounds and medicinal uses thereof |
| 07/13/2000 | WO2000040552A1 Amidomalonamides and their use as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040539A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
| 07/13/2000 | WO2000040275A2 The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
| 07/13/2000 | WO2000040262A1 Novel agents and methods for treatment and diagnosis of ocular disorders |
| 07/13/2000 | WO2000040250A1 Amelometasone lotion |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040241A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | WO2000040239A1 Compounds and methods |
| 07/13/2000 | WO2000040228A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040217A1 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000040087A1 Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors |
| 07/13/2000 | WO2000027363B1 Aerosols comprising nanoparticle drugs |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |